Spruce Biosciences, Inc. Increase (Decrease) in Accrued Liabilities
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Accrued Liabilities of -$1.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-12
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$589.00K.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.30M, a 1028.57% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $1.81M, a 56.62% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.09M.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$2.50M.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$2.27M, a 136.31% decline from fiscal 2023.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $6.25M, a 74.38% increase from fiscal 2022.
- Spruce Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $3.59M, a 55.69% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$589.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.89M 10-Q · filed 2026-08-12 | -$81.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.30M 10-Q · filed 2026-05-13 | $508.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.60M derived: sum of 3 quarters · filed 2026-05-13 | -$3.94M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.90M derived: sum of 2 quarters · filed 2026-03-09 | -$2.64M derived: sum of 3 quarters · filed 2026-08-12 | -$2.50M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$4.45M derived: sum of 2 quarters · filed 2026-08-12 | -$4.31M 10-Q · filed 2025-11-10 | -$142.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$5.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.40M 10-Q · filed 2026-08-12 | -$1.23M derived: sum of 3 quarters · filed 2026-08-12 | -$4.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $140.00K 10-Q · filed 2026-05-13 | $4.31M derived: sum of 2 quarters · filed 2026-05-13 | $948.00K derived: sum of 3 quarters · filed 2026-05-13 | -$777.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $808.00K derived: sum of 2 quarters · filed 2026-03-09 | -$917.00K derived: sum of 3 quarters · filed 2026-03-09 | -$2.27M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$5.08M derived: sum of 2 quarters · filed 2025-11-10 | -$6.44M 10-Q · filed 2025-11-10 | -$2.58M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.08M 10-Q · filed 2025-08-14 | $782.00K derived: sum of 3 quarters · filed 2025-08-14 | $520.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.35M 10-Q · filed 2025-05-06 | $2.51M derived: sum of 2 quarters · filed 2025-05-06 | $2.25M derived: sum of 3 quarters · filed 2025-05-06 | $5.69M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $3.60M derived: sum of 2 quarters · filed 2025-04-15 | $7.05M derived: sum of 3 quarters · filed 2025-04-15 | $6.25M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.19M derived: sum of 2 quarters · filed 2024-11-12 | $2.39M 10-Q · filed 2024-11-12 | $3.48M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.66M 10-Q · filed 2024-08-12 | $3.74M derived: sum of 3 quarters · filed 2024-08-12 | $4.55M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$793.00K 10-Q · filed 2024-05-13 | $288.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.11M derived: sum of 3 quarters · filed 2024-05-13 | $1.58M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $1.90M derived: sum of 2 quarters · filed 2024-03-18 | $2.38M derived: sum of 3 quarters · filed 2024-03-18 | $3.59M 10-K · filed 2024-03-18 |
| 2022-09-30 | $818.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.30M derived: sum of 2 quarters · filed 2023-11-13 | $2.51M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $478.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.69M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $1.21M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $2.30M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |